STOCK TITAN

SpringWorks Therapeutics to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

SpringWorks Therapeutics, a clinical-stage biopharmaceutical company specializing in rare diseases and cancer treatments, announced participation in a Fireside Chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 8, 2021. The event is scheduled for 3:00 PM ET. Interested parties can access the live webcast via the company’s Investors & Media section. A recording will be available afterward. SpringWorks is advancing clinical trials for targeted oncology therapies and has formed partnerships to enhance its portfolio.

Positive
  • None.
Negative
  • None.

STAMFORD, Conn., June 01, 2021 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that management will participate in a Fireside Chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on Tuesday, June 8th at 3:00PM ET.

To access the live webcast please visit the Events & Presentations page within the Investors & Media section of the company’s website at https://ir.springworkstx.com. A replay of the webcast will be available on SpringWorks’ website for a limited time following the conference.

About SpringWorks Therapeutics
SpringWorks is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for patients living with severe rare diseases and cancer. SpringWorks has a differentiated targeted oncology portfolio of small molecule product candidates and is advancing two potentially registrational clinical trials in rare tumor types as well as several other programs addressing highly prevalent, genetically defined cancers. SpringWorks’ strategic approach and operational excellence in clinical development have enabled it to rapidly advance its two lead product candidates into late-stage clinical trials while simultaneously entering into multiple shared-value partnerships with innovators in industry and academia to expand its portfolio to create more solutions for patients with cancer. For more information, visit www.springworkstx.com and follow @SpringWorksTx on Twitter and LinkedIn

Contact:
Kim Diamond
Phone: 203-561-1646
Email: kdiamond@springworkstx.com


FAQ

What event will SpringWorks Therapeutics participate in on June 8, 2021?

SpringWorks Therapeutics will participate in a Fireside Chat at the Goldman Sachs 42nd Annual Global Healthcare Conference.

What time is the Fireside Chat for SpringWorks Therapeutics scheduled?

The Fireside Chat is scheduled for 3:00 PM ET on June 8, 2021.

How can I access the SpringWorks Therapeutics webcast?

The webcast can be accessed through the Events & Presentations page in the Investors & Media section of SpringWorks’ website.

What is the focus of SpringWorks Therapeutics?

SpringWorks Therapeutics focuses on developing medicines for severe rare diseases and cancers using a precision medicine approach.

What type of clinical trials is SpringWorks currently advancing?

SpringWorks is advancing two potentially registrational clinical trials in rare tumor types.

SpringWorks Therapeutics, Inc.

NASDAQ:SWTX

SWTX Rankings

SWTX Latest News

SWTX Stock Data

2.57B
70.75M
1.92%
116.49%
16.52%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
STAMFORD